Unitaid 278d ago

“By bringing the cost of long-acting injectable prevention on par with oral PrEP, countries now have a stronger economic case to scale up access widely,” said Vincent Bretin, Director of Results and Climate and Health at Unitaid. “This is more than a pricing agreement: it is a breakthrough for prevention, equity, and resilience.” Through a new agreement with Dr. Reddy’s Laboratories, the Clinton Health Access Initiative, Wits RHI and Unitaid have secured a $40 annual price for injectable lenacapavir, making it accessible in 120 low- and middle-income countries starting in 2027. This landmark step ensures that a revolutionary HIV prevention tool can reach more people who need protection and demonstrates what is possible when innovation is paired with equity. Learn more: https://unitaid.org/lenacapavir